相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Update on the use of memantine in Alzheimer’s disease
Rob Marum
Neuropsychiatric Disease and Treatment (2010)
Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients
Bengt G. Winblad et al.
Alzheimers & Dementia (2009)
Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: Preliminary results
Martin Bednar et al.
Alzheimers & Dementia (2009)
Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
Ronald B. DeMattos et al.
Alzheimers & Dementia (2009)
Pharmacokinetics and pharmacodynamics of bapineuzumab following multiple intravenous infusions in patients with mild-to-moderate Alzheimer's disease
Murray Raskind et al.
Alzheimers & Dementia (2009)
Characterization of the pharmacokinetics, pharmacodynamics, and distribution of anti-abeta antibody MABT5102A
Deborah Mortensen et al.
Alzheimers & Dementia (2009)
Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo
Ryan J. Watts et al.
Alzheimers & Dementia (2009)
In vivo amyloid deposition and neuropathological findings after humanized amyloid β-specific monoclonal antibodies therapy in a patient with Alzheimer's disease
Oscar L. Lopez et al.
Alzheimers & Dementia (2009)
Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease
Timothy Nicholas et al.
Alzheimers & Dementia (2009)
Applications of neuroimaging to disease-modification trials in Alzheimer's disease
Adam S. Fleisher et al.
BEHAVIOURAL NEUROLOGY (2009)
Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo
G. D. Rabinovici et al.
BEHAVIOURAL NEUROLOGY (2009)
Bridging Physiology and Pathology in AD
Dohoon Kim et al.
CELL (2009)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Michael Shanks et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?
Gregory A. Jicha
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
John Hardy
JOURNAL OF NEUROCHEMISTRY (2009)
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Kaoru Yamada et al.
JOURNAL OF NEUROSCIENCE (2009)
DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER'S DISEASE (AD) - FROM CONCEPT TO CLINICAL TESTING
A. Schneeberger et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
The Role of Apolipoprotein E in Alzheimer's Disease
Jungsu Kim et al.
NEURON (2009)
Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease
Michael Bacher et al.
NEUROSCIENCE LETTERS (2009)
P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Eric R. Siemers et al.
Alzheimers & Dementia (2008)
Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease
D. Munoz-Torrero
CURRENT MEDICINAL CHEMISTRY (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse
Peter Seubert et al.
NEURODEGENERATIVE DISEASES (2008)
Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model
Erik D. Roberson et al.
SCIENCE (2007)
Antibody against C-terminal Abeta selectively elevates plasma Abeta
Audrey J. Gray et al.
NEUROREPORT (2007)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2006)
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
NC Fox et al.
NEUROLOGY (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Passive Immunization of the A beta 42(43) C-Terminal-Specific Antibody BC05 in a Mouse Model of Alzheimer's Disease
Asano Asami-Odaka et al.
NEURODEGENERATIVE DISEASES (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
A beta 42 immunization in Alzheimer's disease generates A beta N-terminal antibodies
M Lee et al.
ANNALS OF NEUROLOGY (2005)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
WE Klunk et al.
ANNALS OF NEUROLOGY (2004)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
I Ferrer et al.
BRAIN PATHOLOGY (2004)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein
K Chalmers et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Passive immunization against β-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation
MH Mohajeri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease
R Dodel et al.
ANNALS OF NEUROLOGY (2002)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart et al.
NATURE NEUROSCIENCE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
C Janus et al.
NATURE (2000)
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
D Morgan et al.
NATURE (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
